• citations in SCIndeks: [1]
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:3
  • full-text downloads in 30 days:2


article: 4 from 17  
Back back to result list
2012, vol. 46, iss. 1, pp. 19-23
Risk factors for morbidity of hepatitis C in opiate addicts
aPsihijatrijska služba, Zdravstveni centar, Valjevo
bClinical Center Kragujevac, Clinic of Psychiatry + Clinical Center Kragujevac
Objective. The aim of this paper is to present the results of serological testing for HCV infection in opiate addicts on methadone maintenance treatment. Method. Serological testing of subjects who were on treatment at Methadone Center, Psychiatry Service of Health Centre in Valjevo was performed between 01/07/2008 and 30/06/2010. For the purpose of this study we used the appropriate questionnaire (Pompidou questionnaire), designed for psychoactive substance abuse researches. The subjects were divided into two groups according to the way opiates were taken. Comparison was made, according to serological status and other predictors, with subgroup analysis for intravenous abusers. Descriptive analysis and hypothesis testing were used for statistical calculations, with a probability of p = <0.05. Results. Serological testing was performed on 72 male subjects. The subjects were divided as follows: 58 people in Group A (intravenous addicts) and 14 patients in Group B (addicts who had not been taking opiates intravenously). The total of 37 subjects from Group A (63.79%) were diagnosed with positive finding of HCV, whereas the HCV was found in 4 subjects (28.57%) from Group B, which was a statistically significant difference (χ2=4.36, p=0.037<0.05). Subgroup analysis of intravenous addicts showed significant relationships between HCV serological status and the following: the highest degree of education (χ2=7.59; p=0.023<0.05), use of common equipment (χ2=5.35; p=0.020<0.05) and duration of intravenous consumption (χ2=4.25; p=0.039). Conclusion. Intravenous consumption of opiates shows significant association with HCV infection while some behavioral and socio-demographic factors increase the risk.
Alter, M.J., Moyer, L.A. (1998) The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol, 18: S6-S10
Betz, C., Mihalic, D., Pinto, M.E., Raffa, R.B. (2000) Could a common biochemical mechanism underlie addictions?. Journal of clinical pharmacy and therapeutics, 25(1): 11-20
Craine, N., Hickman, M., Parry, J.V., Smith, J., Walker, A.M., Russell, D., Nix, B., May, M., McDonald, T., Lyons, M. (2009) Incidence of hepatitis C in drug injectors: The role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and infection, 137(9): 1255-65
Crofts, N., Caruana, S., Bowden, S., Kerger, M. (2000) Minimising harm from hepatitis C virus needs better strategies. BMJ, 321: 899
Dolan, K.A., Shearer, J., White, B., Zhou, J., Kaldor, J., Wodak, A.D. (2005) Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction (Abingdon, England), 100(6): 820-8
Edlin, B.R., Carden, M.R. (2006) Injection drug users: The overlooked core of the hepatitis C epidemic. Clinical infectious diseases, 42(5): 673-6
Fischer, B., Rehm, J., Kim, G., Robins, A. (2002) Safer injection facilities (SIFs) for injection drug users (IDUs) in Canada. A review and call for an evidence-focused pilot trial. Canadian journal of public health. Revue canadienne de santé publique, 93(5): 336-8
Hahn, J.A., Page-Shafer, K., Lum, P.J., Bourgois, P., Stein, E., Evans, J.L., Busch, M.P., Tobler, L.H., Phelps, B., Moss, A.R. (2002) Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Journal of infectious diseases, 186(11): 1558-64
Hallinan, R., Byrne, A., Amin, J., Dore, G.J. (2005) Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. Journal of gastroenterology and hepatology, 20(7): 1082-6
Marsch, L.A. (1998) The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour, and criminality: A metaanalysis. Addiction, 93, str. 515-532
Mijailović, Ž., Gajović, O., Nešić, L., Čanović, P. (2006) Savremena terapija HBeAg negativnog hroninog hepatitisa B. Medicinski časopis, 40(1-2): 59-63
Miller, C.L., Johnston, C., Spittal, P.M., Li, K., Laliberté, N., Montaner, J.S.G., Schechter, M.T. (2002) Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (Baltimore, Md.), 36(3): 737-42
Patrick, D.M., Tyndall, M.W., Cornelisse, P.G., Li, K., Sherlock, C.H., Rekart, M.L., Strathdee, S.A., Currie, S.L., Schechter, M.T., Shaughnessy, O.M.V. (2001) Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ, 165(7): 889-95
Radovanović, D., Radovanović, G., Antić, L. (2010) Promocija zdravlja - sveobuhvatni pristup ka unapređenju zdravlja pojedinca i populacije. PONS - medicinski časopis, vol. 7, br. 4, str. 161-166
Remis, R., Health Canada (2004) A study to characterize the epidemiology of hepatitis C infection in Canada. Ottawa, Final report 2002
Savić, D., Jakovljević, M. (2012) Značaj procene kliničkih ishoda iz ugla pacijenta u donošenju kliničke odluke. Racionalna terapija, vol. 4, br. 1, str. 47-49
Schaefer, M., Heinz, A., Backmund, M. (2004) Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules?. Addiction, 99(9): 1167-75
Shapatava, E., Nelson, K.E., Tsertsvadze, T., Rio, C.del (2006) Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug and Alcohol Dependence, 82: S35-S38
Smyth, B.P. (2003) Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin. Journal of Epidemiology & Community Health, 57(4): 310-311
Smyth, B.P., Barry, J., Keenan, E. (2005) Irish injecting drug users and hepatitis C: The importance of the social context of injecting. International journal of epidemiology, 34(1): 166-72
Strauss, S.M., Astone-Twerell, J., Munoz-Plaza, C.E., et al. (2007) Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res, 7: 39
Svrakić, D., Cloninger, C.R., Svrakić, N., Lazić, B., Milivojević, D., Nastasić, P. (2010) Drug addiction and choice of drugs: Temperament and personality as risk factors. Serbian Journal of Experimental and Clinical Research, vol. 11, br. 3, str. 93-98
Thorpe, L.E., Ouellet, L.J., Hershow, R., Bailey, S.L., Williams, I.T., Williamson, J., Monterroso, E.R., Garfein, R.S. (2002) Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol, 155(7): 645-53
Tortu, S., McMahon, J.M., Pouget, E.R., Hamid, R. (2004) Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Substance use & misuse, 39(2): 211-24
Vasić, G., Mihajlović, G., Rafajlović, M. (2010) Sociodemografska obeležja opijatskih zavisnika - istraživanje obavljeno u Metadonskom centru psihijatrijske službe Zdravstvenog centra u Valjevu. Socijalna misao, vol. 17, br. 1, str. 93-106
Vassilev, Z.P., Hagan, H., Lyubenova, A., Tomov, N., Vasilev, G., Krasteva, D., Des, J.D.C. (2006) Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users. International journal of STD & AIDS, 17(9): 621-6
Zou, S., Forrester, L., Giulivi, A. (2003) Hepatitis C update. Canadian journal of public health. Revue canadienne de santé publique, 94(2): 127-9


article language: Serbian
document type: Professional Paper
DOI: 10.5937/mckg46-2100
published in SCIndeks: 09/07/2012